RS Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History

RS Investment Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$98.4M	Sell	1,322,074 -140,736	-10%	-$10.4M	1.01%	13
2016 Q1	$97.7M	Sell	1,462,810 -284,027	-16%	-$17.3M	0.97%	16
2015 Q4	$118M	Sell	1,746,837 -464,069	-21%	-$28.7M	1.06%	16
2015 Q3	$118M	Buy	2,210,906 +635,221	+40%	+$38.5M	1.05%	11
2015 Q2	$99.2M	Sell	1,575,685 -327,878	-17%	-$17.9M	0.85%	20
2015 Q1	$91.6M	Sell	1,903,563 -389,769	-17%	-$14.9M	0.82%	27
2014 Q4	$76.1M	Sell	2,293,332 -100,965	-4%	-$3.28M	0.68%	35
2014 Q3	$70.2M	Buy	2,394,297 +162,624	+7%	+$5.4M	0.65%	45
2014 Q2	$86.7M	Buy	2,231,673 +271,994	+14%	+$11M	0.73%	30
2014 Q1	$82.2M	Sell	1,959,679 -148,423	-7%	-$6.19M	0.48%	52
2013 Q4	$69.2M	Buy	2,108,102 +1,160,136	+122%	+$37.8M	0.42%	65
2013 Q3	$25.6M	Buy	+947,966	New	+$26.7M	0.17%	158

Other funds holding LGND

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RS Investment Management's LGND Position: Q2 2016 in Review

RS Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 9.6% in Q2 2016, selling an estimated $10.4M and leaving 1,322,074 shares worth $98.4M. The position accounts for 1.01% of the portfolio, ranked #13.

RS Investment Management first reported a position in LGND in Q3 2013 and has held it in 12 quarters since. The position peaked at $118M in Q4 2015. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2016.

RS Investment Management held 1,322,074 shares of Ligand Pharmaceuticals worth $98.4M as of Q2 2016.
RS Investment Management sold 140,736 Ligand Pharmaceuticals shares in Q2 2016, an estimated $10.4M.
Ligand Pharmaceuticals made up 1.01% of RS Investment Management's portfolio in Q2 2016, its #13 holding.
RS Investment Management first reported a position in Ligand Pharmaceuticals in Q3 2013 and has held it in 12 quarters since.
RS Investment Management's Ligand Pharmaceuticals position peaked at $118M in Q4 2015.
265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.